Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.5%

1 terminated/withdrawn out of 68 trials

Success Rate

93.3%

+6.7% vs industry average

Late-Stage Pipeline

10%

7 trials in Phase 3/4

Results Transparency

0 of 14 completed trials have results

Key Signals

20 recruiting

Enrollment Performance

Analytics

Phase 2

21(45.7%)

N/A

15(32.6%)

Phase 3

5(10.9%)

Phase 1

3(6.5%)

Phase 4

2(4.3%)

46Total

Phase 2(21)

N/A(15)

Phase 3(5)

Phase 1(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (68)

Showing 20 of 68 trials

NCT07841210Phase 2Active Not Recruiting

Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors

Role: collaborator

NCT05801133Phase 2Completed

Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors

Role: lead

NCT06714084Not ApplicableEnrolling By Invitation

CNCMT：a Multi-center, Prospective, Single-arm Study

Role: lead

NCT05004441Phase 2Completed

Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer

Role: collaborator

NCT07807722Phase 2Not Yet Recruiting

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

Role: lead

NCT07250204Recruiting

A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.

Role: lead

NCT07264985Recruiting

Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib

Role: lead

NCT07209787Phase 4Recruiting

SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

Role: collaborator

NCT07002346Phase 3Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator

NCT05780372Phase 3Active Not Recruiting

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Role: collaborator

NCT07541001Phase 2Active Not Recruiting

PRL3-Zumab in Patients With Advanced Solid Tumors

Role: collaborator

NCT07405346Not ApplicableEnrolling By Invitation

A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy

Role: collaborator

NCT07263347Not Yet Recruiting

DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes

Role: lead

NCT07264998Not Yet Recruiting

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

Role: lead

NCT07188857Not Yet Recruiting

Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy

Role: lead

NCT02605265Phase 3Completed

Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1

Role: collaborator

NCT06280313Recruiting

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

Role: collaborator

NCT06402435Phase 2Recruiting

SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer

Role: lead

NCT07011329Active Not Recruiting

Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.

Role: lead

NCT05044871Phase 2Completed

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Role: collaborator